Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 95

1.

Limb-Girdle Muscular Dystrophy: A perspective from adult patients on what matters most.

Hunter M, Heatwole C, Wicklund M, Weihl CC, Mozaffar T, Statland JM, Johnson NE.

Muscle Nerve. 2019 Jul 12. doi: 10.1002/mus.26636. [Epub ahead of print]

PMID:
31298728
2.

SMCHD1 mutation spectrum for facioscapulohumeral muscular dystrophy type 2 (FSHD2) and Bosma arhinia microphthalmia syndrome (BAMS) reveals disease-specific localisation of variants in the ATPase domain.

Lemmers RJLF, van der Stoep N, Vliet PJV, Moore SA, San Leon Granado D, Johnson K, Topf A, Straub V, Evangelista T, Mozaffar T, Kimonis V, Selvatici R, Ferlini A, Voermans N, van Engelen B, Sacconi S, Tawil R, Lamers M, van der Maarel SM.

J Med Genet. 2019 Jun 26. pii: jmedgenet-2019-106168. doi: 10.1136/jmedgenet-2019-106168. [Epub ahead of print]

PMID:
31243061
3.

Randomized phase 2 study of FcRn antagonist efgartigimod in generalized myasthenia gravis.

Howard JF Jr, Bril V, Burns TM, Mantegazza R, Bilinska M, Szczudlik A, Beydoun S, Garrido FJRR, Piehl F, Rottoli M, Van Damme P, Vu T, Evoli A, Freimer M, Mozaffar T, Ward ES, Dreier T, Ulrichts P, Verschueren K, Guglietta A, de Haard H, Leupin N, Verschuuren JJGM; Efgartigimod MG Study Group.

Neurology. 2019 Jun 4;92(23):e2661-e2673. doi: 10.1212/WNL.0000000000007600. Epub 2019 May 22.

PMID:
31118245
4.

A phase 3 randomized study evaluating sialic acid extended-release for GNE myopathy.

Lochmüller H, Behin A, Caraco Y, Lau H, Mirabella M, Tournev I, Tarnopolsky M, Pogoryelova O, Woods C, Lai A, Shah J, Koutsoukos T, Skrinar A, Mansbach H, Kakkis E, Mozaffar T.

Neurology. 2019 Apr 30;92(18):e2109-e2117. doi: 10.1212/WNL.0000000000006932. Epub 2019 Jan 25.

5.

Homozygosity for the A431E mutation in PSEN1 presenting with a relatively aggressive phenotype.

Parker J, Mozaffar T, Messmore A, Deignan JL, Kimonis VE, Ringman JM.

Neurosci Lett. 2019 Apr 23;699:195-198. doi: 10.1016/j.neulet.2019.01.047. Epub 2019 Feb 1.

PMID:
30716424
6.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BRF, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Verschuuren JJGM, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Silvestri NJ, Conwit R, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

Lancet Neurol. 2019 Mar;18(3):259-268. doi: 10.1016/S1474-4422(18)30392-2. Epub 2019 Jan 25.

PMID:
30692052
7.

Expanding the importance of HMERF titinopathy: new mutations and clinical aspects.

Palmio J, Leonard-Louis S, Sacconi S, Savarese M, Penttilä S, Semmler AL, Kress W, Mozaffar T, Lai T, Stojkovic T, Berardo A, Reisin R, Attarian S, Urtizberea A, Cobo AM, Maggi L, Kurbatov S, Nikitin S, Milisenda JC, Fatehi F, Raimondi M, Silveira F, Hackman P, Claeys KG, Udd B.

J Neurol. 2019 Mar;266(3):680-690. doi: 10.1007/s00415-019-09187-2. Epub 2019 Jan 21.

8.

Genetic landscape and novel disease mechanisms from a large LGMD cohort of 4656 patients.

Nallamilli BRR, Chakravorty S, Kesari A, Tanner A, Ankala A, Schneider T, da Silva C, Beadling R, Alexander JJ, Askree SH, Whitt Z, Bean L, Collins C, Khadilkar S, Gaitonde P, Dastur R, Wicklund M, Mozaffar T, Harms M, Rufibach L, Mittal P, Hegde M.

Ann Clin Transl Neurol. 2018 Dec 1;5(12):1574-1587. doi: 10.1002/acn3.649. eCollection 2018 Dec.

9.

Review process for IVIg treatment: Lessons learned from INSIGHTS neuropathy study.

Levine TD, Katz JS, Barohn R, Vaughan LJ, Dimachkie MM, Saperstein DS, Mozaffar T, Wolfe GI, Mayo MS, Badger GJ, Katzin L, Ritt E, Greer M, DiStefano J, Schmidt PM.

Neurol Clin Pract. 2018 Oct;8(5):429-436. doi: 10.1212/CPJ.0000000000000520. Review.

10.

Longitudinal Screening Detects Cognitive Stability and Behavioral Deterioration in ALS Patients.

Woolley S, Goetz R, Factor-Litvak P, Murphy J, Hupf J, Lomen-Hoerth C, Andrews H, Heitzman D, Bedlack R, Katz J, Barohn R, Sorenson E, Oskarsson B, Filho AF, Kasarskis E, Mozaffar T, Nations S, Swenson A, Koczon-Jaremko A, Christodoulou G, Mitsumoto H.

Behav Neurol. 2018 Oct 31;2018:5969137. doi: 10.1155/2018/5969137. eCollection 2018.

11.

Safety, tolerability, and preliminary efficacy of an IGF-1 mimetic in patients with spinal and bulbar muscular atrophy: a randomised, placebo-controlled trial.

Grunseich C, Miller R, Swan T, Glass DJ, El Mouelhi M, Fornaro M, Petricoul O, Vostiar I, Roubenoff R, Meriggioli MN, Kokkinis A, Guber RD, Budron MS, Vissing J, Soraru G, Mozaffar T, Ludolph A, Kissel JT, Fischbeck KH; BVS857 study group.

Lancet Neurol. 2018 Dec;17(12):1043-1052. doi: 10.1016/S1474-4422(18)30320-X. Epub 2018 Oct 15.

PMID:
30337273
12.

Rasagiline for amyotrophic lateral sclerosis: A randomized, controlled trial.

Statland JM, Moore D, Wang Y, Walsh M, Mozaffar T, Elman L, Nations SP, Mitsumoto H, Fernandes JA, Saperstein D, Hayat G, Herbelin L, Karam C, Katz J, Wilkins HM, Agbas A, Swerdlow RH, Santella RM, Dimachkie MM, Barohn RJ; Rasagiline Investigators of the Muscle Study Group and Western ALS Consortium.

Muscle Nerve. 2019 Feb;59(2):201-207. doi: 10.1002/mus.26335. Epub 2018 Nov 26.

PMID:
30192007
13.

A cross-sectional analysis of clinical evaluation in 35 individuals with mutations of the valosin-containing protein gene.

Plewa J, Surampalli A, Wencel M, Milad M, Donkervoort S, Caiozzo VJ, Goyal N, Mozaffar T, Kimonis V.

Neuromuscul Disord. 2018 Sep;28(9):778-786. doi: 10.1016/j.nmd.2018.06.007. Epub 2018 Jun 27.

PMID:
30097247
14.

Novel Therapeutic Options in Treatment of Idiopathic Inflammatory Myopathies.

Goyal NA, Mozaffar T.

Curr Treat Options Neurol. 2018 Jul 23;20(9):37. doi: 10.1007/s11940-018-0521-6. Review.

PMID:
30033499
15.

Mexiletine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial.

Oskarsson B, Moore D, Mozaffar T, Ravits J, Wiedau-Pazos M, Parziale N, Joyce NC, Mandeville R, Goyal N, Cudkowicz ME, Weiss M, Miller RG, McDonald CM.

Muscle Nerve. 2018 Mar 6. doi: 10.1002/mus.26117. [Epub ahead of print]

PMID:
29510461
16.

Genotype-phenotype study in patients with valosin-containing protein mutations associated with multisystem proteinopathy.

Al-Obeidi E, Al-Tahan S, Surampalli A, Goyal N, Wang AK, Hermann A, Omizo M, Smith C, Mozaffar T, Kimonis V.

Clin Genet. 2018 Jan;93(1):119-125. doi: 10.1111/cge.13095.

17.

Duvoglustat HCl Increases Systemic and Tissue Exposure of Active Acid α-Glucosidase in Pompe Patients Co-administered with Alglucosidase α.

Kishnani P, Tarnopolsky M, Roberts M, Sivakumar K, Dasouki M, Dimachkie MM, Finanger E, Goker-Alpan O, Guter KA, Mozaffar T, Pervaiz MA, Laforet P, Levine T, Adera M, Lazauskas R, Sitaraman S, Khanna R, Benjamin E, Feng J, Flanagan JJ, Barth J, Barlow C, Lockhart DJ, Valenzano KJ, Boudes P, Johnson FK, Byrne B.

Mol Ther. 2017 May 3;25(5):1199-1208. doi: 10.1016/j.ymthe.2017.02.017. Epub 2017 Mar 22.

18.

Mortality and Causes of Death in Patients with Sporadic Inclusion Body Myositis: Survey Study Based on the Clinical Experience of Specialists in Australia, Europe and the USA.

Price MA, Barghout V, Benveniste O, Christopher-Stine L, Corbett A, de Visser M, Hilton-Jones D, Kissel JT, Lloyd TE, Lundberg IE, Mastaglia F, Mozaffar T, Needham M, Schmidt J, Sivakumar K, DeMuro C, Tseng BS.

J Neuromuscul Dis. 2016 Mar 3;3(1):67-75.

19.

Sporadic inclusion body myositis misdiagnosed as idiopathic granulomatous myositis.

Lavian M, Goyal N, Mozaffar T.

Neuromuscul Disord. 2016 Nov;26(11):741-743. doi: 10.1016/j.nmd.2016.09.003. Epub 2016 Sep 13.

PMID:
27692540
20.

Randomized Trial of Thymectomy in Myasthenia Gravis.

Wolfe GI, Kaminski HJ, Aban IB, Minisman G, Kuo HC, Marx A, Ströbel P, Mazia C, Oger J, Cea JG, Heckmann JM, Evoli A, Nix W, Ciafaloni E, Antonini G, Witoonpanich R, King JO, Beydoun SR, Chalk CH, Barboi AC, Amato AA, Shaibani AI, Katirji B, Lecky BR, Buckley C, Vincent A, Dias-Tosta E, Yoshikawa H, Waddington-Cruz M, Pulley MT, Rivner MH, Kostera-Pruszczyk A, Pascuzzi RM, Jackson CE, Garcia Ramos GS, Verschuuren JJ, Massey JM, Kissel JT, Werneck LC, Benatar M, Barohn RJ, Tandan R, Mozaffar T, Conwit R, Odenkirchen J, Sonett JR, Jaretzki A 3rd, Newsom-Davis J, Cutter GR; MGTX Study Group.

N Engl J Med. 2016 Aug 11;375(6):511-22. doi: 10.1056/NEJMoa1602489. Erratum in: N Engl J Med. 2017 May 25;376(21):2097. [Dosage error in article text].

21.

Critically re-evaluating a common technique: Accuracy, reliability, and confirmation bias of EMG.

Charles JA, Souayah N, Narayanaswami P, Jones L, Weiss M, Mozaffar T, Rutkove SB.

Neurology. 2016 Aug 9;87(6):645. doi: 10.1212/WNL.0000000000003023. No abstract available.

PMID:
27502964
22.

Prospective exploratory muscle biopsy, imaging, and functional assessment in patients with late-onset Pompe disease treated with alglucosidase alfa: The EMBASSY Study.

van der Ploeg A, Carlier PG, Carlier RY, Kissel JT, Schoser B, Wenninger S, Pestronk A, Barohn RJ, Dimachkie MM, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Guglieri M, Young P, Boentert M, Baudin PY, Wens S, Shafi R, Bjartmar C, Thurberg BL.

Mol Genet Metab. 2016 Sep;119(1-2):115-23. doi: 10.1016/j.ymgme.2016.05.013. Epub 2016 May 19.

23.

A randomized controlled trial of methotrexate for patients with generalized myasthenia gravis.

Pasnoor M, He J, Herbelin L, Burns TM, Nations S, Bril V, Wang AK, Elsheikh BH, Kissel JT, Saperstein D, Shaibani JA, Jackson C, Swenson A, Howard JF Jr, Goyal N, David W, Wicklund M, Pulley M, Becker M, Mozaffar T, Benatar M, Pazcuzzi R, Simpson E, Rosenfeld J, Dimachkie MM, Statland JM, Barohn RJ; Methotrexate in MG Investigators of the Muscle Study Group.

Neurology. 2016 Jul 5;87(1):57-64. doi: 10.1212/WNL.0000000000002795. Epub 2016 Jun 15.

24.

Defining SOD1 ALS natural history to guide therapeutic clinical trial design.

Bali T, Self W, Liu J, Siddique T, Wang LH, Bird TD, Ratti E, Atassi N, Boylan KB, Glass JD, Maragakis NJ, Caress JB, McCluskey LF, Appel SH, Wymer JP, Gibson S, Zinman L, Mozaffar T, Callaghan B, McVey AL, Jockel-Balsarotti J, Allred P, Fisher ER, Lopate G, Pestronk A, Cudkowicz ME, Miller TM.

J Neurol Neurosurg Psychiatry. 2017 Feb;88(2):99-105. doi: 10.1136/jnnp-2016-313521. Epub 2016 Jun 3.

25.

Tongue atrophy and fasciculations in transthyretin familial amyloid neuropathy: An ALS mimicker.

Goyal NA, Mozaffar T.

Neurol Genet. 2015 Jul 30;1(2):e18. doi: 10.1212/NXG.0000000000000018. eCollection 2015 Aug.

26.

Cognitive-behavioral screening reveals prevalent impairment in a large multicenter ALS cohort.

Murphy J, Factor-Litvak P, Goetz R, Lomen-Hoerth C, Nagy PL, Hupf J, Singleton J, Woolley S, Andrews H, Heitzman D, Bedlack RS, Katz JS, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Koczon-Jaremko BA, Mitsumoto H; ALS COSMOS.

Neurology. 2016 Mar 1;86(9):813-20. doi: 10.1212/WNL.0000000000002305. Epub 2016 Jan 22.

27.

Pulmonary function tests (maximum inspiratory pressure, maximum expiratory pressure, vital capacity, forced vital capacity) predict ventilator use in late-onset Pompe disease.

Johnson EM, Roberts M, Mozaffar T, Young P, Quartel A, Berger KI.

Neuromuscul Disord. 2016 Feb;26(2):136-45. doi: 10.1016/j.nmd.2015.11.009. Epub 2015 Nov 30.

28.

Critically re-evaluating a common technique: Accuracy, reliability, and confirmation bias of EMG.

Narayanaswami P, Geisbush T, Jones L, Weiss M, Mozaffar T, Gronseth G, Rutkove SB.

Neurology. 2016 Jan 19;86(3):218-23. doi: 10.1212/WNL.0000000000002292. Epub 2015 Dec 23.

29.

Editorial by concerned physicians: Unintended effect of the orphan drug act on the potential cost of 3,4-diaminopyridine.

Burns TM, Smith GA, Allen JA, Amato AA, Arnold WD, Barohn R, Benatar M, Bird SJ, Bromberg M, Chahin N, Ciafaloni E, Cohen JA, Corse A, Crum BA, David WS, Dimberg E, Sousa EA, Donofrio PD, Dyck PJ, Engel AG, Ensrud ER, Ferrante M, Freimer M, Gable KL, Gibson S, Gilchrist JM, Goldstein JM, Gooch CL, Goodman BP, Gorelov D, Gospe SM Jr, Goyal NA, Guidon AC, Guptill JT, Gutmann L, Gutmann L, Gwathmey K, Harati Y, Harper CM Jr, Hehir MK, Hobson-Webb LD, Howard JF Jr, Jackson CE, Johnson N, Jones SM, Juel VC, Kaminski HJ, Karam C, Kennelly KD, Khella S, Khoury J, Kincaid JC, Kissel JT, Kolb N, Lacomis D, Ladha S, Larriviere D, Lewis RA, Li Y, Litchy WJ, Logigian E, Lou JS, MacGowen DJ, Maselli R, Massey JM, Mauermann ML, Mathews KD, Meriggioli MN, Miller RG, Moon JS, Mozaffar T, Nations SP, Nowak RJ, Ostrow LW, Pascuzzi RM, Peltier A, Ruzhansky K, Richman DP, Ross MA, Rubin DI, Russell JA, Sachs GM, Salajegheh MK, Saperstein DS, Scelsa S, Selcen D, Shaibani A, Shieh PB, Silvestri NJ, Singleton JR, Smith BE, So YT, Solorzano G, Sorenson EJ, Srinivasen J, Tavee J, Tawil R, Thaisetthawatkul P, Thornton C, Trivedi J, Vernino S, Wang AK, Webb TA, Weiss MD, Windebank AJ, Wolfe GI.

Muscle Nerve. 2016 Feb;53(2):165-8. doi: 10.1002/mus.25009. Epub 2015 Dec 21. No abstract available.

PMID:
26662952
30.

GMPPB-Associated Dystroglycanopathy: Emerging Common Variants with Phenotype Correlation.

Jensen BS, Willer T, Saade DN, Cox MO, Mozaffar T, Scavina M, Stefans VA, Winder TL, Campbell KP, Moore SA, Mathews KD.

Hum Mutat. 2015 Dec;36(12):1159-63. doi: 10.1002/humu.22898. Epub 2015 Sep 23.

31.

Diagnostic value of MRI in inflammatory myositis.

Lai TT, Mozaffar T.

Neurol Neuroimmunol Neuroinflamm. 2015 Jul 9;2(4):e128. doi: 10.1212/NXI.0000000000000128. eCollection 2015 Aug. No abstract available.

32.

Desert hedgehog is a mediator of demyelination in compression neuropathies.

Jung J, Frump D, Su J, Wang W, Mozaffar T, Gupta R.

Exp Neurol. 2015 Sep;271:84-94. doi: 10.1016/j.expneurol.2015.04.014. Epub 2015 May 1.

PMID:
25936873
33.

Seropositivity for NT5c1A antibody in sporadic inclusion body myositis predicts more severe motor, bulbar and respiratory involvement.

Goyal NA, Cash TM, Alam U, Enam S, Tierney P, Araujo N, Mozaffar FH, Pestronk A, Mozaffar T.

J Neurol Neurosurg Psychiatry. 2016 Apr;87(4):373-8. doi: 10.1136/jnnp-2014-310008. Epub 2015 Apr 9.

34.

Activation of the Wnt/β-catenin signaling cascade after traumatic nerve injury.

Kurimoto S, Jung J, Tapadia M, Lengfeld J, Agalliu D, Waterman M, Mozaffar T, Gupta R.

Neuroscience. 2015 May 21;294:101-8. doi: 10.1016/j.neuroscience.2015.02.049. Epub 2015 Mar 3.

35.

An overview of polymyositis and dermatomyositis.

Findlay AR, Goyal NA, Mozaffar T.

Muscle Nerve. 2015 May;51(5):638-56. doi: 10.1002/mus.24566. Review.

36.

Topical tranexamic Acid does not affect electrophysiologic or neurovascular sciatic nerve markers in an animal model.

Schwarzkopf R, Dang P, Luu M, Mozaffar T, Gupta R.

Clin Orthop Relat Res. 2015 Mar;473(3):1074-82. doi: 10.1007/s11999-014-4098-4. Epub 2015 Jan 6.

37.

A Phase 4 Prospective Study in Patients with Adult Pompe Disease Treated with Alglucosidase Alfa.

Thurberg BL, Carlier P, Kissel JT, Schoser B, Pestronk A, Barohn RJ, Goker-Alpan O, Mozaffar T, Pena LD, Simmons Z, Straub V, Young P, Shafi R, Bjartmar C, van der Ploeg A.

J Neuromuscul Dis. 2015;2(s1):S72-S73. No abstract available.

PMID:
27858658
38.

Experimental trials in amyotrophic lateral sclerosis: a review of recently completed, ongoing and planned trials using existing and novel drugs.

Goyal NA, Mozaffar T.

Expert Opin Investig Drugs. 2014 Nov;23(11):1541-51. doi: 10.1517/13543784.2014.933807. Epub 2014 Jun 26. Review.

PMID:
24965719
39.

Early Surgical Decompression Restores Neurovascular Blood Flow and Ischemic Parameters in an in Vivo Animal Model of Nerve Compression Injury.

Jung J, Hahn P, Choi B, Mozaffar T, Gupta R.

J Bone Joint Surg Am. 2014 Jun 4;96(11):897-906. Epub 2014 Jun 4.

40.

Patient characteristics and comorbidities associated with cerebrovascular accident following acute myocardial infarction in the United States.

Naderi N, Masoomi H, Mozaffar T, Malik S.

Int J Cardiol. 2014 Aug 1;175(2):323-7. doi: 10.1016/j.ijcard.2014.05.024. Epub 2014 May 16.

41.

Hypercaloric enteral nutrition in patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled phase 2 trial.

Wills AM, Hubbard J, Macklin EA, Glass J, Tandan R, Simpson EP, Brooks B, Gelinas D, Mitsumoto H, Mozaffar T, Hanes GP, Ladha SS, Heiman-Patterson T, Katz J, Lou JS, Mahoney K, Grasso D, Lawson R, Yu H, Cudkowicz M; MDA Clinical Research Network.

Lancet. 2014 Jun 14;383(9934):2065-2072. doi: 10.1016/S0140-6736(14)60222-1. Epub 2014 Feb 28.

42.

ALS Multicenter Cohort Study of Oxidative Stress (ALS COSMOS): study methodology, recruitment, and baseline demographic and disease characteristics.

Mitsumoto H, Factor-Litvak P, Andrews H, Goetz RR, Andrews L, Rabkin JG, McElhiney M, Nieves J, Santella RM, Murphy J, Hupf J, Singleton J, Merle D, Kilty M, Heitzman D, Bedlack RS, Miller RG, Katz JS, Forshew D, Barohn RJ, Sorenson EJ, Oskarsson B, Fernandes Filho JA, Kasarskis EJ, Lomen-Hoerth C, Mozaffar T, Rollins YD, Nations SP, Swenson AJ, Shefner JM, Andrews JA, Koczon-Jaremko BA; ALS COSMOS Study Group.

Amyotroph Lateral Scler Frontotemporal Degener. 2014 Jun;15(3-4):192-203. doi: 10.3109/21678421.2013.864312. Epub 2014 Feb 24.

43.

Respiratory and nutritional support in amyotrophic lateral sclerosis.

Goyal NA, Mozaffar T.

Curr Treat Options Neurol. 2014 Feb;16(2):270. doi: 10.1007/s11940-013-0270-5.

PMID:
24390801
44.

Lipid-enriched diet rescues lethality and slows down progression in a murine model of VCP-associated disease.

Llewellyn KJ, Nalbandian A, Jung KM, Nguyen C, Avanesian A, Mozaffar T, Piomelli D, Kimonis VE.

Hum Mol Genet. 2014 Mar 1;23(5):1333-44. doi: 10.1093/hmg/ddt523. Epub 2013 Oct 24.

45.

ALS Untangled No. 20: the Deanna protocol.

ALSUntangled Group, Fournier C, Bedlack B, Hardiman O, Heiman-Patterson T, Gutmann L, Bromberg M, Ostrow L, Carter G, Kabashi E, Bertorini T, Mozaffar T, Andersen P, Dietz J, Gamez J, Dimachkie M, Wang Y, Wicks P, Heywood J, Novella S, Rowland LP, Pioro E, Kinsley L, Mitchell K, Glass J, Sathornsumetee S, Kwiecinski H, Baker J, Atassi N, Forshew D, Ravits J, Conwit R, Jackson C, Sherman A, Dalton K, Tindall K, Gonzalez G, Robertson J, Phillips L, Benatar M, Sorenson E, Shoesmith C, Nash S, Maragakis N, Moore D, Caress J, Boylan K, Armon C, Grosso M, Gerecke B, Wymer J, Oskarsson B, Bowser R, Drory V, Shefner J, Lechtzin N, Leitner M, Miller R, Mitsumoto H, Levine T, Russell J, Sharma K, Saperstein D, McClusky L, MacGowan D, Licht J, Verma A, Strong M, Lomen-Hoerth C, Tandan R, Rivner M, Kolb S, Polak M, Rudnicki S, Kittrell P, Quereshi M, Sachs G, Pattee G, Weiss M, Kissel J, Goldstein J, Rothstein J, Pastula D, Gleb L, Ogino M, Rosenfeld J, Carmi E, Oster C, Barkhaus P, Valor E.

Amyotroph Lateral Scler Frontotemporal Degener. 2013 May;14(4):319-23. doi: 10.3109/21678421.2013.788405. Epub 2013 May 2. Review. No abstract available.

PMID:
23638638
46.

The effects of adjuvant fibrin sealant on the surgical repair of segmental nerve defects in an animal model.

Rafijah G, Bowen AJ, Dolores C, Vitali R, Mozaffar T, Gupta R.

J Hand Surg Am. 2013 May;38(5):847-55. doi: 10.1016/j.jhsa.2013.01.044. Epub 2013 Apr 3.

PMID:
23561728
47.

A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis.

Howard JF Jr, Barohn RJ, Cutter GR, Freimer M, Juel VC, Mozaffar T, Mellion ML, Benatar MG, Farrugia ME, Wang JJ, Malhotra SS, Kissel JT; MG Study Group.

Muscle Nerve. 2013 Jul;48(1):76-84. doi: 10.1002/mus.23839. Epub 2013 Apr 30.

PMID:
23512355
48.

Novel GNE mutations in autosomal recessive hereditary inclusion body myopathy patients.

No D, Valles-Ayoub Y, Carbajo R, Khokher Z, Sandoval L, Stein B, Tarnopolsky MA, Mozaffar T, Darvish B, Pietruszka M, Darvish D.

Genet Test Mol Biomarkers. 2013 May;17(5):376-82. doi: 10.1089/gtmb.2012.0408. Epub 2013 Feb 25.

PMID:
23437777
49.

Matrix metalloproteinase 3 deletion preserves denervated motor endplates after traumatic nerve injury.

Chao T, Frump D, Lin M, Caiozzo VJ, Mozaffar T, Steward O, Gupta R.

Ann Neurol. 2013 Feb;73(2):210-23. doi: 10.1002/ana.23781. Epub 2012 Dec 31.

PMID:
23281061
50.

A Review of Spasticity Treatments: Pharmacological and Interventional Approaches.

Chang E, Ghosh N, Yanni D, Lee S, Alexandru D, Mozaffar T.

Crit Rev Phys Rehabil Med. 2013;25(1-2):11-22.

Supplemental Content

Loading ...
Support Center